Locationú║HOME >> NEWS >> In The Spotlight
Potential Zika Virus Therapies Identified by Miao Xu and Other Researchers
2016-09-29 OnClick: 465
The Zika virus has been reported in 60 countries and territories worldwide; currently, there are no vaccines or effective drug treatments. In response to the current global health emergency posed by the Zika virus (ZIKV) outbreak and its link to the birth defect microcephaly and other neurological conditions like Guillain-Barre syndrome, Dr. Miao Xu and other American scientists performed a drug repurposing screen of ~6,000 compounds that included approved drugs, clinical trial drug candidates and pharmacologically active compounds; they identified compounds that either inhibit ZIKV infection or suppress infection-induced caspase-3 activity in different neural cells. A pan-caspase inhibitor, emricasan, inhibited ZIKV-induced increases in caspase-3 activity and protected human cortical neural progenitors in both monolayer and three-dimensional organoid cultures. Ten structurally unrelated inhibitors of cyclin-dependent kinases inhibited ZIKV replication. Niclosamide, a category B anthelmintic drug approved by the US Food and Drug Administration, also inhibited ZIKV replication. Finally, combination treatments using one compound from each category (neuroprotective and antiviral) further increased protection of human neural progenitors and astrocytes from ZIKV-induced cell death. Their results demonstrate the efficacy of this screening strategy and identify lead compounds for anti-ZIKV drug development.
The research “Identification of small molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen”, published on August 29th, 2016 in the journal Nature Medicine (impact factor: 30.357). The release of all the compound screening data in this publication and in the public PubChem database opens the door to the research community to accelerate the translational process of finding a potential therapy. “The research could help quicken discovery of medications for Zika and help prevent the neurological disorders associated with it, including microcephaly,” the Wall Street Journal reported on the same day.